

Quantiferon in the Diagnosis of Tuberculosis

Hamida Amer ^{1*}, Amal Ouhida ²

¹ Department of pharmacy, high institute of sciences and medical technology abuslaim.

² Department of Medical laboratory, high institute of sciences and medical technology abuslaim.

***Corresponding Author:** Hamida Amer, Department of Pharmacy, High Institute of Sciences and Medical Technology Abuslaim.

Received Date: September 04, 2023 | **Accepted Date:** September 25, 2023 | **Published Date:** October 02, 2023

Citation: Amer H., Ouhida A., (2023), Quantiferon in the Diagnosis of Tuberculosis, *International Journal of Clinical Case Reports and Reviews*, 14(5); DOI:10.31579/2690-4861/338

Copyright: © 2023, Hamida Amer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract:

Quantiferon test (QFT) is an indirect diagnostic test for latent tuberculosis (TB) infection and active TB. Objectives: The aim of this study is to investigate the role of Quantiferon-TB Gold test as one of the interferon-gamma release assays (IGRAs) in detecting LTBI.

Research methodology: This study was conducted at private lab in Tripoli during the period from October 2022 to January 2023, Diagnosis of 254 sample recorded. QFT was performed in accordance with the manufacturer's instructions.

Results: The study include (n= 254 cases), (58 sample 22.8 %) show positive results by Quantiferon test while (196 sample 77.1%) show negative test. Females constituted 118 (46.4%) of the total cases, while the males constituted 136 (53.6%). the age (31-40 years) for the negative includes (35 cases 13.7%) while (41-50 years and (61-70 years) for positive include (11cases 4.3%).

Discussion: This study confirmed previous reports that the QFT test had greater sensitivity for detecting active TB than the 100-year-old TST.

Conclusion: It was concluded that the quantiferon TB-2G test is a more useful diagnostic method for tuberculosis infection. QFT-Plus assay showed good sensitivity for active TB and was particularly useful for the evaluation of children with suspected LTBI, giving a low rate of indeterminate results in this group. More studies are needed to properly evaluate QFT-Plus ability in discriminating active disease from latent infection.

Key words: tuberculosis; quantiferon; diagnostic; QFT-plus; LTBI

1.Introduction

Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis*. Tuberculosis typically attacks the lungs, but can also affect other parts of the body. The disease has become rare in high income countries, but is still a major public health problem in low- and middle-income countries [1].

Tuberculosis (TB) continues to be a global public health problem. According to the World Health Organization (WHO) Global TB Report, one-third of the world population is infected with *Mycobacterium Tuberculosis*. Individuals with latent tuberculosis infection (LTBI) have a 10 percent risk of developing active TB disease during their lifetime, especially in the first two years. Diagnosis of LTBI and its treatment in high-risk populations are considered to be main components of TB control programmes [7].

Diagnosis of TB is usually based on a combination of anamnestic symptoms, clinical presentation, radiological and pathological changes, bacteriological findings of acid/alcohol-fast bacilli and molecular tests. A

definitive TB diagnosis is usually based on culture of a mycobacterium of the *Mycobacterium tuberculosis* complex (MTB) [8].

Therefore, tools that can assist the clinician with the initial diagnosis of active TB are important, because antituberculous treatment takes several months and carries a risk of serious side-effects [5]. Two such diagnostic tools are the tuberculin skin test (TST) and the QuantiFERON®-TB Gold test (QFT). The TST measures delayed-type hypersensitivity reactions to a crude mixture of mycobacterial antigens which are also present in *Bacille Calmette–Guérin* (BCG) vaccine strains and non-tuberculous mycobacteria. QFT is based on the measurement of interferon-gamma (IFN- γ) secreted from T cells previously exposed to MTB when stimulated in vitro [8,9].

It is estimated that between the years 2000 and 2010, eight to nine million new cases emerged each year. Approximately 1.5 million people die from the disease each year. In adults, tuberculosis is the second leading cause of death due to an infectious disease (after AIDS), with 95% of deaths occurring in low- income countries. Tuberculosis is a major problem of

children in poor countries where it kills over 100,000 children each year [2].

Tuberculosis is an airborne disease caused by the bacterium *Mycobacterium tuberculosis* (*M. tuberculosis*). *M. tuberculosis* and seven very closely related mycobacterial species (*M. bovis*, *M. africanum*, *M. microti*, *M. caprae*, *M. pinnipedii*, *M. canetti* and *M. mungi*) together comprise what is known as the *M. tuberculosis* complex [1].

The human tubercle bacillus (*Mycobacterium tuberculosis*) is the main cause of tuberculosis all over the world. A slightly different type of TB, *Mycobacterium africanum*, occurs in Africa. The only important difference is that it is often resistant to thioacetazone [1].

The bovine bacillus (*Mycobacterium bovis*) at one time caused much infection in cattle in Europe and the Americas. Infection was often passed on to man through contaminated milk. Bovine TB in milk can be killed by boiling the milk, and bovine tuberculosis rarely occurs where this is the practice. The extent of the transmission of bovine tuberculosis to humans is difficult to determine because of technical problems in isolating the organisms. One important difference is the resistance to pyrazinamide in *M. bovis* [1].

Diagnosing and initiating effective treatment in a patient early in the course of their TB disease, before they can infect many people, is considered the most effective preventive measure against TB. Effective treatment substantially reduces or eliminates disease transmission from smear-positive patients in less than one month after initiation of treatment [1].

BCG is a vaccine consisting of live bacilli have lost their power to cause disease (except in persons with profound immunodeficiency). The bacilli originally came from a strain of bovine TB grown for many years in the laboratory. BCG stimulates immunity, increasing the body's defences without itself causing damage. Following BCG vaccination, in most cases the body's increased defences will control or kill any TB that enter the body [2,3].

The current recommendation by the WHO and the International Union Against Tuberculosis and Lung Disease (The Union) is that in countries with high prevalence of tuberculosis, BCG should be given routinely to all infants (but with a few exceptions, such as those known to have HIV infection and children of mothers with HIV infection at high risk of TB transmission). The normal dose in neonates and infants is 0.05 ml [1].

M. tuberculosis is transmitted from human-to-human and is mainly spread by airborne route. The source of infection is a patient with pulmonary or laryngeal tuberculosis (TB) who expectorates bacilli. During coughing, speaking, or sneezing, the patient produces tiny infectious droplets. These particles, called droplet nuclei, are about 1 to 5 microns in diameter—about 1-5/1000 of millimeter. Droplet nuclei can remain suspended in the air for several hours, depending on the environment [1].

Transmission may occur when these infectious droplets are inhaled. Sunlight, UV light and ventilation are effective in decreasing the ability of the droplets reaching the lung.

The other modes of transmission are far less common. Cutaneous or mucous inoculation rarely occurs, although such cases have been

observed in laboratory personnel. A rare cause of digestive transmission of TB can occur with *M. bovis*, most commonly through cow's milk [1].

The infectiousness of a patient is linked to the quantity of bacilli contained in his sputa. Patients with sputum smear-positive microscopy are by far the most contagious. Those with smear-negative/culture- positive results are less contagious. Patients whose sputum smear microscopy and culture are both negative are usually not contagious.

Patients who are infected with *M. tuberculosis*, but do not have active disease, cannot transmit TB. Extrapulmonary (EP) forms of TB are only contagious in exceptional circumstances. Children are generally much less contagious than adults. This may be due to weaker cough mechanics, less sputum production and lower bacillary load [4].

Not everyone who is exposed to an infectious TB patient becomes infected with *M. tuberculosis*. The probability that TB will be transmitted depends on three factors:

A. Contagiousness of the source (the greatest factor):

- Bacteriological status: smear-positive being the most infectious.
- Virulence of the tubercle bacilli: certain strains are very transmissible (and/or more likely to cause active disease).

B. Environment where the exposure occurred:

- Open air and sunlight are conditions less likely to lead to transmission, whereas small rooms/settings with no ventilation are the conditions most likely to lead to transmission.
- the proximity of the person to the patient is also important (i.e., sleeping next to the patient in the ward versus sleeping 20 meters away) [6].

C. Duration of exposure:

Close contacts of TB patients are at highest risk of becoming infected with *M. tuberculosis*. They may be family members, roommates, friends, co-workers or others who spend multiple hours per day with the TB patient while the person is infectious.

The best way to stop transmission is to start giving patients effective TB treatment as soon as possible.

The length of time required for a TB patient to become non-infectious after starting TB therapy is not exactly known. However, once an effective TB therapy is started, as long as the patient follows the prescribed treatment regimen, there is considerable evidence showing the infectiousness can rapidly decline, even after a few days [5].

1.1. Diagnosis of TB

1.1.1. The skin tests

The skin test is a widely used test for diagnosing TB. In countries with low rates of TB it is often used to test for latent TB infection. The problem with using it in countries with high rates of TB infection is that the majority of people may have latent TB (figure 1) [8].



Figure 1: Test for *M. tuberculosis* Infection.

The skin test involves injecting a small amount of fluid (called tuberculin) into the skin in the lower part of the arm. Then the person must return after 48 to 72 hours to have a trained health care worker look at their arm. The health care worker will look for a raised hard area or swelling, and if there is one then they will measure its size. They will not include any general area of redness [9,10].

The test result depends on the size of the raised hard area or swelling. The larger the size of the affected area the greater the likelihood that the person has been infected with TB bacteria at some time in the past. But interpreting the TB skin test result, that is whether it is a positive result, may also involve considering the lifestyle factors of the person being tested for TB. The TB skin test also cannot tell if the person has latent TB or active TB disease [11].

1.1.2 TB Interferon gamma release assays (IGRAs):

IGRAs are blood-based tests assessing the presence of effector and memory immune responses directed against the *M. tuberculosis* antigens. The IGRAs have been shown to predominantly measure the presence of *M. tuberculosis* specific effector memory T-cells, the presence of which are considered indicative of previous *in vivo* exposure to the bacilli. Blood samples might also contain central memory T-cells specific to the *M. tuberculosis* antigens and thus be measured in the assays. The latter is however seen as less likely, as this subset of cells react more slowly to antigen exposure and is considered to first release other cytokines during the time-span of the assays (e.g., interleukin-2) [10]. The IGRAs measure the presence of an adaptive immune response to *M. tuberculosis* antigens, and are thus only an indirect measure of *M. tuberculosis* exposure (evidence is still lacking as to whether an immune response corresponds to actual infection). IGRAs have been developed for the identification of an immune response to *M. tuberculosis*- specific antigens, considered to be a correlate of *M. tuberculosis* infection, and are licensed for the use on blood specimens [11].

The Interferon Gamma Release Assays (IGRAs) are a new type of more accurate TB test. In this context referring to an assay is simply a way of referring to a test or procedure [11,18].

IGRAs are blood tests that measure a person's immune response to the bacteria that cause TB. The immune system produces some special molecules called cytokines. These TB tests work by detecting a cytokine called the interferon gamma cytokine. In practice you carry out one of

these TB tests by taking a blood sample and mixing it with special substances to identify if the cytokine is present [12,13].

There are two commercially available IGRAs:

1. Quantiferon-TB Gold In-Tube assay:

The Quantiferon-TB Gold In-Tube assay (QFT-GIT), which has replaced the Quantiferon-TB Gold assay, detects the level of IFN- γ produced in response to the *M. tuberculosis* antigens, and uses the enzyme-linked immunosorbent assay (ELISA) detection method. This is an indirect measure of the presence of *M. tuberculosis* specific T-cells [14] (figure3).

2. T-SPOT.TB assay:

The T-SPOT.TB measures the number of IFN- γ producing T-cells in response to the *M. tuberculosis* antigens, and is based on the enzyme-linked immunosorbent spot (ELISPOT) assay (figure1). Only the two commercially available IGRAs (QFT-GIT and T-SPOT.TB), both with standardized and licensed protocols that allow the comparison of study results [15, 16,17].

2. Materials and Methods

QuantIFERON test (QFT) is an indirect diagnostic test for latent tuberculosis (TB) infection and active TB. The aim of this study is to investigate the role of QuantIFERON-TB Gold test as one of the interferon- gamma release assays (IGRAs) in detecting LTBI.

This study was conducted at private lab in Tripoli during the period from October 2022 to January 2023, Diagnosis of 254 sample recorded. QFT was performed in accordance with the manufacturer's instructions.

2.1 Quantiferon-TB Gold In-Tube assay (QFT-GIT)

IGRAs are performed on fresh blood specimens. The QFT-GIT is performed by drawing 1 ml of blood into one of each of the three manufacturer-precoated, heparinized tubes. Within 16 hours of blood collection, the tubes must be incubated for another 16 to 24 hours at 37 °C [19,20]. The plasma is harvested after centrifugation (QFT-GIT collection tubes contain a gel plug that separates the plasma from the cells when centrifuged) and used (immediately, or later, provided there is adequate storage) to assess the concentration of IFN- γ by ELISA test. Results are interpreted according to the manufacturer's recommendations table 1.

Interpretation criteria for the QuantiFERON-TB Gold In-Tube assay (QFT-GIT)²⁰

Result	IFN-γ concentration (International Units per ml, IU/ml)	Nil	PHA nil
	<i>M. tuberculosis</i> antigens	Nil	PHA nil
Positive	≥ 0.35 IU/ml and ≥ 25% over nil	≤ 8.0 IU/ml	Any
Negative	< 0.35 IU/ml or < 25% over nil	≤ 8.0 IU/ml	≥ 0.5 IU/ml
Indeterminate	<0.35 IU/ml or < 25% over nil	≤ 8.0 IU/ml	< 0.5 IU/ml
	Any	> 8.0 IU/ml	Any

Table 1: Interpretation Criteria for The Quantiferon-Tb Gold In-Tube Assay (QFT-GIT)

3. Results:

Table 2 shows the study include (n= 254 cases), (58 sample 22.8 %) show positive results by Quantiferon test while (196 sample 77.1%) show

negative test. Females constituted 118 (46.4%) of the total cases (figure 3), while the males constituted 136 (53.6%) (figure 2). the age (31-40 years) for the negative includes (35 cases 13.7%) while (41-50 years and (61-70 years) for positive include (11cases 4.3%).

Age	Positive			Negative		
	Male	Female	Total	Male	Female	Total
1-10 years	00	01	01	06	04	10
11-20 years	03	05	08	17	09	26
21-30 years	04	03	07	20	13	33
31-40 years	05	05	10	19	16	35
41-50 years	03	08	11	21	09	30
51-60 years	02	04	06	08	14	22
61-70 years	04	07	11	14	11	25
71-80 years	02	01	03	07	04	11
81-90 years	00	01	01	01	03	04
	TOTAL=23	TOTAL=35		TOTAL=113	TOTAL= 83	
	TOTAL =58			TOTAL = 196		
	TOTAL =254					

Table 2: Comparison of the Results of The Quantiferontb Gold Test (QFT)




Figure 2: Shows The Percentages of Different Age Groups (Positive Male)




Figure 3: Shows The Percentages of Different Age Groups (Positive Female)

4. Discussion:

This study confirmed previous reports that the QFT test had greater sensitivity for detecting active TB than the 100-year-old TST.

The guidelines of the Center for Disease Control and Prevention (CDC) in Europe do not recommend the use of IGRAs in countries with a high incidence of TB [1]. In addition, TST appears to be the most viable option in low-and middle-income countries because of its low cost [21,22]. However, although TST has been extensively studied, there is still some discrepancy between the optimal TST cutoff point for LTBI diagnosis and subsequent isoniazid treatment recommended by the Ministry of Health ($\geq 5\text{mm}$) [11] and the professional practice ($\geq 10\text{mm}$).

Previous studies have shown that the sensitivity of QuantiFERON-TB Gold In TUBE® and TST is approximately 80% [26]. However, IGRAs has a specificity > 95% in the diagnosis of LTBI [23,24,25]. The specificity of TST is affected by previous BCG vaccination; specificity values reach 97% in unvaccinated populations, while in populations extensively vaccinated with BCG, it is approximately 60% [22]. However, BCG vaccination administered up to the age of one does not interfere with TST results after 10 years [23,24,25].

5. Conclusions

It was concluded that the QuantiFERON TB-2G test is a more useful diagnostic method for tuberculosis infection. QFT-Plus assay showed good sensitivity for active TB and was particularly useful for the evaluation of children with suspected LTBI, giving a low rate of indeterminate results in this group. More studies are needed to properly evaluate QFT-Plus ability in discriminating active disease from latent infection.

Conflict of interests: The authors declare no conflicts of interest regarding the publication of this paper

Authors' contribution: All the authors contributed equally to prepare this article, read, and approved the final manuscript.

7. References

- 1 Hans L. Rieder, Chiang Chen- Yuan, Robert P. Gie, Donald A. Enarson, (2009). Clinical Tuberculosis.
- 2 Francis Varaine, Michael L. (2017). Rich Médecins Sans Frontières and Partners in Health. Tuberculosis: Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries.
- 3 Grzybowski S. Tuberculosis. (1983). A look at the world situation. *Chest*. 84(6):756–761.
- 4 Nardell Edward, (2012). personal communication, Partners in Health and Harvard School of Public Health, Boston USA.
- 5 Jindani A, Aber VR, Edwards EA, Mitchison DA. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. *Am. Rev. Respir. Dis*. 121(6):939–949.
- 6 Fortun J, Martin-Davila P, Molina A, Navas E, Hermida JM, et al. (2007). Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? *J Antimicrob Chemother*. 27;59(4):794–798.
- 7 Heubner RE, Schein MF, Bass JB Jr. (1993). The tuberculin skin test. *Clin Infect Dis*. 17: 968–975.
- 8 Mirtskhulava V, Kempker R, Shields KL, Leonard MK, Tsertsvadze T, et al. (2008). Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia. *Int J Tuberc Lung Dis*. 12: 513-519.
- 9 Ciftci F, Sezer O, Kaya H, Tozkoparan E, Bozkanat E, et al. (2011). Comparison of tuberculin skin test and QuantiFERON-TB Gold test in young adult male patient with pulmonary tuberculosis. *T Klin J Med Sci*. 31: 534-540.
- 10 Russell DG. (2001). Mycobacterium tuberculosis: here today, and here tomorrow. *Nat Rev Mol Cell Biol* 2:569-577.
- 11 Vergne I, Chua J, Singh SB, Deretic V. (2004). Cell biology of mycobacterium tuberculosis phagosome. *Annu Rev Cell Dev Biol*; 20:367-394.
- 12 Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, et al. (1999). Mice deficient in CD4 T-cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. *J Immunol*; 162:5407-5416.

- 13 Nathan CF, Murray HW, Wiebe ME, Rubin BY. (1983). Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J Exp Med*; 158:670-689.
- 14 Cellestis.com. Carnegie, Victoria, Australia: c2007. QuantiFERON-TB Gold In-Tube Results Interpretation Guide.
- 15 Oxford Immunotec. (2009). T-SPOT.TB technical handbook. Abingdon, UK: Oxford Immunotec.
- 16 Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, et al. (2010). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, *MMWR Recomm Rep*; 59:1-25.
- 17 European Centre for Disease Prevention and Control (ECDC). (2011). Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: ECDC.
- 18 Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, et al. (2011). Interferon- γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. *J Infect Dis*; 204:1-10.
- 19 Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, et al. (2011). Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. *Eur Respir J*; 37: 100-111.
- 20 Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D Mwansa-Kambafwile J, et al. (2012). Predictive value of interferon- γ release assays for incident active tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis*. 12:4.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Manuscript](#)

DOI:10.31579/2690-4861/338

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/international-journal-of-clinical-case-reports-and-reviews>